Personalized Neoantigen-based Dendritic Cell Vaccine (Likang Life Sciences)

个性化肿瘤新生抗原树突状细胞疫苗（立康生命科技）

Report date: 2022/12/31 19:25:33

Base Information

Drug NamePersonalized Neoantigen-based Dendritic Cell Vaccine (Likang Life Sciences)
Drug Alias NameLK-Neo DC荷载肿瘤新生抗原的树突状细胞药物Neoantigen Vaccines
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPancreatic NeoplasmsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Likang Life Science and Tech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSichuan University
Inactive CompaniesLikang Life Sciences Holdings Ltd
Active IndicationsPancreatic Neoplasms
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A